INmune Bio Inc (INMB) - Total Assets
Based on the latest financial reports, INmune Bio Inc (INMB) holds total assets worth $33.36 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore INMB debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
INmune Bio Inc - Total Assets Trend (2015–2024)
This chart illustrates how INmune Bio Inc's total assets have evolved over time, based on quarterly financial data. See what is INmune Bio Inc's book value for net asset value and shareholders' equity analysis.
INmune Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
INmune Bio Inc's total assets of $33.36 Million consist of 57.3% current assets and 42.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.9% |
| Accounts Receivable | $1.41 Million | 3.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $16.51 Million | 41.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how INmune Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see INMB market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INmune Bio Inc's current assets represent 57.3% of total assets in 2024, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 52.9% of total assets in 2024, down from 100.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 41.7% of total assets.
INmune Bio Inc Competitors by Total Assets
Key competitors of INmune Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
INmune Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.17 | 2.59 | 13.50 |
| Quick Ratio | 4.17 | 2.70 | 13.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $23.31 Million | $22.03 Million | $22.21 Million |
INmune Bio Inc - Advanced Valuation Insights
This section examines the relationship between INmune Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.40 |
| Latest Market Cap to Assets Ratio | 0.88 |
| Asset Growth Rate (YoY) | -30.6% |
| Total Assets | $39.56 Million |
| Market Capitalization | $34.83 Million USD |
Valuation Analysis
Near Book Valuation: The market values INmune Bio Inc's assets close to their book value (0.88x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: INmune Bio Inc's assets decreased by 30.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for INmune Bio Inc (2015–2024)
The table below shows the annual total assets of INmune Bio Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $39.56 Million | -30.59% |
| 2023-12-31 | $57.00 Million | -30.31% |
| 2022-12-31 | $81.80 Million | -18.16% |
| 2021-12-31 | $99.94 Million | +145.83% |
| 2020-12-31 | $40.66 Million | +66.14% |
| 2019-12-31 | $24.47 Million | +40.93% |
| 2018-12-31 | $17.36 Million | -5.70% |
| 2017-12-31 | $18.41 Million | +3977.32% |
| 2016-12-31 | $451.61K | +3700.77% |
| 2015-12-31 | $11.88K | -- |
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of pati… Read more